|
|
|||
|
||||
OverviewEvery year, millions of people face life-threatening illnesses for which effective treatments are limited or nonexistent. Yet only a small fraction of patients participates in clinical trials, even though these studies are vital to developing new therapies. Fewer than 8 percent of adult cancer patients take part in these trials, with even lower rates among Black and Hispanic populations. This gap is not merely due to a lack of interest; the clinical trial process can be daunting, often leaving patients and their families uninformed, unprepared and overwhelmed. This book offers a much-needed, clear, balanced, and comprehensive guidance at a moment when patient-centered care has never been more important. It demystifies how trials work, what patients can expect, and how to weigh the promise of cutting-edge treatments against the challenges and potential risks involved. It simultaneously empowers patients and caregivers to make informed decisions, turning a process that can feel intimidating into one that is understandable, navigable, and ultimately hopeful. Full Product DetailsAuthor: Jose-Alberto PalmaPublisher: Bloomsbury Publishing PLC Imprint: Bloomsbury Academic Dimensions: Width: 14.60cm , Height: 2.60cm , Length: 21.80cm Weight: 0.680kg ISBN: 9798881842475Pages: 296 Publication Date: 30 April 2026 Audience: General/trade , General Format: Hardback Publisher's Status: Forthcoming Availability: Manufactured on demand Table of ContentsReviewsAlberto Palma has written a terrific book. It speaks directly to clinical trial participants, but those of us conducting the studies will find it equally engaging and rewarding. To the point, well-organized, and full of valuable information. -- Horacio Kaufmann Author InformationJose-Alberto Palma, MD, PhD, is a physician-scientist with more than fifteen years of experience in clinical trials and drug development. He is dedicated to advancing medical research and improving patient care. Dr. Palma currently serves as global clinical lead for neurodegeneration programs at Eli Lily, a role he formerly held at Novartis. Tab Content 6Author Website:Countries AvailableAll regions |
||||